The story of mRNA: From a loose idea to a tool that may help curb Covid
The story of mRNA began is a tale of personal perseverance, eureka moments in the lab, soaring expectations — and an unprecedented flow of cash in biotech.
A NDOVER, Mass. — The liquid that many hope could help end the Covid-19 pandemic is stored in a nondescript metal tank in a manufacturing complex owned by Pfizer, one of the world’s biggest drug companies. There is nothing remarkable about the container, which could fit in a walk-in closet, except that its contents could end up in the world’s first authorized Covid-19 vaccine. Pfizer, a 171-year-old Fortune 500 powerhouse, has made a billion-dollar bet on that dream. So has a brash, young rival just 23 miles away in Cambridge, Mass. Moderna, a 10-year-old biotech company with billions in marke
Explore this link on the map →related reading
- Progress Deferred: mRNA Vaccine Development Lessons | IFPifp.org
- Making Vaccine — LessWronglesswrong.com
- Why are mRNA vaccines so exciting? - Harvard Healthhealth.harvard.edu
- The story of VaccinateCA - Works in Progress Magazineworksinprogress.co
- What most surprised experts about the Covid pandemic | STATstatnews.com
- Reasons to be pessimistic (and optimistic) on the future of biosecurityowlposting.com
- The tangled history of mRNA vaccinesnature.com
- Explaining Biden’s Pandemic Preparedness Budget: ASPRprogress.institute
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- What We Learned Doing Fast Grants | Futurefuture.a16z.com
- It's Time to Build | Andreessen Horowitza16z.com
- PopVax develops RNA vaccines and cancer immunotherapies to save 1 million lives each yearpopvax.com